Together with reports that RUNX1 mutations are associated with resistance to DNA-damaging chemotherapy in AML [46, 47] these observations led us to test whether RUNX1 loss reduces sensitivity to CHK1 inhibitors in splicing-factor–mutated hematopoietic progenitors. This evidence concerns the gene CHEK1 and acute myeloid leukemia.